{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:50:50Z","timestamp":1773715850134,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110036"],"award-info":[{"award-number":["2020A1515110036"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030313578"],"award-info":[{"award-number":["2017A030313578"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Project of Guangzhou","award":["201707010276"],"award-info":[{"award-number":["201707010276"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700489"],"award-info":[{"award-number":["81700489"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Director Foundation of Nanfang Hospital","award":["2023A044"],"award-info":[{"award-number":["2023A044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03647-y","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:12:23Z","timestamp":1738329143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quantitative proteomic studies of the intestinal mucosa provide new insights into the molecular mechanism of ulcerative colitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Yandong","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahal","family":"Pabitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanbo","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Side","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"3647_CR1","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1136\/gutjnl-2019-318936","volume":"68","author":"GR Jones","year":"2019","unstructured":"Jones GR, Lyons M, Plevris N, Jenkinson PW, Bisset C, Burgess C, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut. 2019;68:1953\u201360.","journal-title":"Gut"},{"key":"3647_CR2","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1002\/ibd.22916","volume":"18","author":"JR Goodhand","year":"2012","unstructured":"Goodhand JR, Wahed M, Mawdsley JE, Farmer AD, Aziz Q, Rampton DS. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis. 2012;18:2301\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"3647_CR3","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.mayocp.2019.01.018","volume":"94","author":"JD Feuerstein","year":"2019","unstructured":"Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357\u201373.","journal-title":"Mayo Clin Proc"},{"key":"3647_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.crohns.2013.09.009","volume":"8","author":"DJ Mulder","year":"2014","unstructured":"Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8:341\u20138.","journal-title":"J Crohns Colitis"},{"key":"3647_CR5","doi-asserted-by":"publisher","first-page":"3950628","DOI":"10.1155\/2019\/3950628","volume":"2019","author":"L Ning","year":"2019","unstructured":"Ning L, Shan G, Sun Z, Zhang F, Xu C, Lou X, et al. Quantitative proteomic analysis reveals the deregulation of nicotinamide adenine dinucleotide metabolism and CD38 in inflammatory bowel disease. Biomed Res Int. 2019;2019:3950628.","journal-title":"Biomed Res Int"},{"key":"3647_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jprot.2019.04.009","volume":"201","author":"T Lehmann","year":"2019","unstructured":"Lehmann T, Schallert K, Vilchez-Vargas R, Benndorf D, P\u00fcttker S, Sydor S, et al. Metaproteomics of fecal samples of Crohn\u2019s disease and Ulcerative Colitis. J Proteom. 2019;201:93\u2013103.","journal-title":"J Proteom"},{"key":"3647_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426\u201331.","journal-title":"Gut"},{"key":"3647_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/gut.27.7.809","volume":"27","author":"SH Saverymuttu","year":"1986","unstructured":"Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn\u2019s disease and ulcerative colitis. Gut. 1986;27:809\u201313.","journal-title":"Gut"},{"key":"3647_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1080\/00365521.2017.1344875","volume":"52","author":"C Smids","year":"2017","unstructured":"Smids C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, Wahab PJ, et al. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52:1104\u201312.","journal-title":"Scand J Gastroenterol"},{"key":"3647_CR10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1572-0241.2001.03613.x","volume":"96","author":"M Peeters","year":"2001","unstructured":"Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of Anti-saccharomyces Cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730\u20134.","journal-title":"Am J Gastroenterol"},{"key":"3647_CR11","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066\u201378.","journal-title":"N Engl J Med"},{"key":"3647_CR12","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/gb-2012-13-9-r79","volume":"13","author":"XC Morgan","year":"2012","unstructured":"Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79.","journal-title":"Genome Biol"},{"key":"3647_CR13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2012-303955","volume":"62","author":"MZ Cader","year":"2013","unstructured":"Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62:1653\u201364.","journal-title":"Gut"},{"key":"3647_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/pmic.201700164","volume":"17","author":"M Moriggi","year":"2017","unstructured":"Moriggi M, Pastorelli L, Torretta E, Tontini GE, Capitanio D, Bogetto SF, et al. Contribution of Extracellular Matrix and Signal Mechanotransduction to epithelial cell damage in inflammatory bowel Disease patients: a proteomic study. Proteomics. 2017;17:23\u20134.","journal-title":"Proteomics"},{"key":"3647_CR15","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1136\/gutjnl-2015-310705","volume":"66","author":"AE Starr","year":"2017","unstructured":"Starr AE, Deeke SA, Ning Z, Chiang CK, Zhang X, Mottawea W, et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn\u2019s disease from UC. Gut. 2017;66:1573\u201383.","journal-title":"Gut"},{"key":"3647_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1074\/mcp.M115.050138","volume":"15","author":"T Riaz","year":"2016","unstructured":"Riaz T, Sollid LM, Olsen I, de Souza GA. Quantitative proteomics of gut-derived Th1 and Th1\/Th17 clones reveal the Presence of CD28\u2009+\u2009NKG2D- Th1 cytotoxic CD4\u2009+\u2009T cells. Mol Cell Proteom. 2016;15:1007\u201316.","journal-title":"Mol Cell Proteom"},{"key":"3647_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","volume":"20","author":"MF Neurath","year":"2019","unstructured":"Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20:970\u20139.","journal-title":"Nat Immunol"},{"key":"3647_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40259-021-00496-5","volume":"35","author":"NJ Wyatt","year":"2021","unstructured":"Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting leukocyte trafficking in inflammatory bowel disease. BioDrugs. 2021;35:473\u2013503.","journal-title":"BioDrugs"},{"key":"3647_CR19","doi-asserted-by":"publisher","first-page":"S633","DOI":"10.1093\/ecco-jcc\/jjy011","volume":"12","author":"J Panes","year":"2018","unstructured":"Panes J, Salas A, Past. Present and Future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease. J Crohns Colitis. 2018;12:S633\u201340.","journal-title":"J Crohns Colitis"},{"key":"3647_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CEG.S293272","volume":"14","author":"J Gubatan","year":"2021","unstructured":"Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives. Clin Exp Gastroenterol. 2021;14:333\u201342.","journal-title":"Clin Exp Gastroenterol"},{"key":"3647_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2019.02.021","volume":"850","author":"YH Li","year":"2019","unstructured":"Li YH, Sun W, Zhou BJ, Rosenstein A, Zhao J, Wang J, et al. iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promising therapy for ulcerative colitis. Eur J Pharmacol. 2019;850:167\u201379.","journal-title":"Eur J Pharmacol"},{"key":"3647_CR22","doi-asserted-by":"publisher","first-page":"114919","DOI":"10.1016\/j.taap.2020.114919","volume":"391","author":"EA Arafa","year":"2020","unstructured":"Arafa EA, Mohamed WR, Zaher DM, Omar HA. Gliclazide attenuates acetic acid-induced colitis via the modulation of PPARgamma, NF-kappaB and MAPK signaling pathways. Toxicol Appl Pharmacol. 2020;391:114919.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3647_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.bcp.2017.03.013","volume":"135","author":"Y Fu","year":"2017","unstructured":"Fu Y, Ma J, Shi X, Song XY, Yang Y, Xiao S, et al. A novel pyrazole-containing indolizine derivative suppresses NF-kappaB activation and protects against TNBS-induced colitis via a PPAR-gamma-dependent pathway. Biochem Pharmacol. 2017;135:126\u201338.","journal-title":"Biochem Pharmacol"},{"key":"3647_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2020.00730","volume":"11","author":"J Decara","year":"2020","unstructured":"Decara J, Rivera P, L\u00f3pez-Gambero AJ, Serrano A, Pav\u00f3n FJ, Baixeras E, et al. Peroxisome proliferator-activated receptors: experimental targeting for the treatment of Inflammatory Bowel diseases. Front Pharmacol. 2020;11:730.","journal-title":"Front Pharmacol"},{"key":"3647_CR25","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0016-5085(03)00262-2","volume":"124","author":"K Katayama","year":"2003","unstructured":"Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology. 2003;124:1315\u201324.","journal-title":"Gastroenterology"},{"key":"3647_CR26","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.4081\/ejh.2022.3415","volume":"66","author":"Y Long","year":"2022","unstructured":"Long Y, Zhao Y, Ma X, Zeng Y, Hu T, Wu W, et al. Endoplasmic reticulum stress contributed to inflammatory bowel disease by activating p38 MAPK pathway. Eur J Histochem. 2022;66:3415.","journal-title":"Eur J Histochem"},{"key":"3647_CR27","doi-asserted-by":"publisher","first-page":"6049500","DOI":"10.1155\/2022\/6049500","volume":"2022","author":"BL Rodrigues","year":"2022","unstructured":"Rodrigues BL, Dotti I, Pascoal LB, Morari J, Esteller M, Coope A, et al. Endoplasmic Reticulum Stress in Colonic Mucosa of Ulcerative Colitis Patients Is Mediated by PERK and IRE1 Pathway Activation. Mediators Inflamm. 2022;2022:6049500.","journal-title":"Mediators Inflamm"},{"key":"3647_CR28","doi-asserted-by":"publisher","first-page":"697360","DOI":"10.3389\/fphar.2021.697360","volume":"12","author":"D Qiao","year":"2021","unstructured":"Qiao D, Zhang Z, Zhang Y, Chen Q, Chen Y, Tang Y, et al. Regulation of endoplasmic reticulum Stress-Autophagy: a potential therapeutic target for Ulcerative Colitis. Front Pharmacol. 2021;12:697360.","journal-title":"Front Pharmacol"},{"key":"3647_CR29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/MIB.0000000000000660","volume":"22","author":"SS Cao","year":"2016","unstructured":"Cao SS. Epithelial ER stress in Crohn\u2019s Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2016;22:984\u201393.","journal-title":"Inflamm Bowel Dis"},{"key":"3647_CR30","doi-asserted-by":"publisher","first-page":"47079","DOI":"10.1074\/jbc.M308124200","volume":"278","author":"DC Sullivan","year":"2003","unstructured":"Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulsom R, Creamer D, et al. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem. 2003;278:47079\u201388.","journal-title":"J Biol Chem"},{"key":"3647_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5582\/irdr.2019.01139","volume":"9","author":"Q Lu","year":"2020","unstructured":"Lu Q, Wang J, Zhang X, Tian R, Qiao L, Ge L, et al. TXNDC5 protects synovial fibroblasts of rheumatoid arthritis from the detrimental effects of endoplasmic reticulum stress. Intractable Rare Dis Res. 2020;9:23\u20139.","journal-title":"Intractable Rare Dis Res"},{"key":"3647_CR32","first-page":"935","volume":"42","author":"F Tan","year":"2018","unstructured":"Tan F, Zhu H, He X, Yu N, Zhang X, Xu H, et al. Role of TXNDC5 in tumorigenesis of colorectal cancer cells: in vivo and in vitro evidence. Int J Mol Med. 2018;42:935\u201345.","journal-title":"Int J Mol Med"},{"key":"3647_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12929-022-00850-x","volume":"29","author":"CT Hung","year":"2022","unstructured":"Hung CT, Tsai YW, Wu YS, Yeh CF, Yang KC. The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. J Biomed Sci. 2022;29:63.","journal-title":"J Biomed Sci"},{"key":"3647_CR34","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1161\/CIRCRESAHA.117.312130","volume":"122","author":"YC Shih","year":"2018","unstructured":"Shih YC, Chen CL, Zhang Y, Mellor RL, Kanter EM, Fang Y, et al. Endoplasmic reticulum protein TXNDC5 augments myocardial fibrosis by facilitating Extracellular Matrix protein folding and Redox-Sensitive Cardiac Fibroblast activation. Circ Res. 2018;122:1052\u201368.","journal-title":"Circ Res"},{"key":"3647_CR35","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1038\/s41467-020-18047-x","volume":"11","author":"TH Lee","year":"2020","unstructured":"Lee TH, Yeh CF, Lee YT, Shih YC, Chen YT, Hung CT, et al. Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFbeta signaling through TGFBR1 stabilization. Nat Commun. 2020;11:4254.","journal-title":"Nat Commun"},{"key":"3647_CR36","doi-asserted-by":"publisher","first-page":"e143645","DOI":"10.1172\/JCI143645","volume":"131","author":"YT Chen","year":"2021","unstructured":"Chen YT, Jhao PY, Hung CT, Wu YF, Lin SJ, Chiang WC, et al. Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-beta signaling in kidney fibroblasts. J Clin Invest. 2021;131:e143645.","journal-title":"J Clin Invest"},{"key":"3647_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ibd\/izab251","volume":"28","author":"G Bamias","year":"2022","unstructured":"Bamias G, Pizarro TT, Cominelli F. Immunological regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022;28:337\u201349.","journal-title":"Inflamm Bowel Dis"},{"key":"3647_CR38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/ecco-jcc\/jjy201","volume":"13","author":"S Lovisa","year":"2019","unstructured":"Lovisa S, Genovese G, Danese S. Role of epithelial-to-mesenchymal transition in inflammatory bowel disease. J Crohns Colitis. 2019;13:659\u201368.","journal-title":"J Crohns Colitis"},{"key":"3647_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41588-018-0063-6","volume":"50","author":"D Kotlarz","year":"2018","unstructured":"Kotlarz D, Marquardt B, Bar\u00f8y T, Lee WS, Konnikova L, Hollizeck S, et al. Human TGF-beta1 deficiency causes severe inflammatory bowel disease and encephalopathy. Nat Genet. 2018;50:344\u20138.","journal-title":"Nat Genet"},{"key":"3647_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fphar.2019.00162","volume":"10","author":"SM Yun","year":"2019","unstructured":"Yun SM, Kim SH, Kim EH. The molecular mechanism of transforming growth factor-beta signaling for intestinal fibrosis: a Mini-review. Front Pharmacol. 2019;10:162.","journal-title":"Front Pharmacol"},{"key":"3647_CR41","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3390\/genes13091570","volume":"13","author":"JK Nowak","year":"2022","unstructured":"Nowak JK, Szyma\u0144ska CJ, Glapa-Nowak A, Duclaux-Loras R, Dybska E, Ostrowski J, et al. Unexpected actors in inflammatory bowel Disease revealed by machine learning from whole-blood Transcriptomic Data. Genes (Basel). 2022;13:1570.","journal-title":"Genes (Basel)"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03647-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:14:33Z","timestamp":1738329273000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03647-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3647"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03647-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"25 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University, and written informed consent was obtained from each patient (registration ID: NFEC-202303-K29). All the procedures were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approve the final draft of the manuscript and provide consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}